Envestnet Asset Management Inc. Has $54.25 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Envestnet Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 118,964 shares of the biopharmaceutical company’s stock after buying an additional 23,168 shares during the quarter. Envestnet Asset Management Inc. owned 0.09% of Alnylam Pharmaceuticals worth $54,248,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ALNY. Root Financial Partners LLC purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. ORG Partners LLC grew its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $39,000. Finally, Hilltop National Bank acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at $41,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Tolga Tanguler sold 1,510 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president directly owned 29,728 shares in the company, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 56,955 shares of company stock valued at $24,072,733. 1.20% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 2.5%

Alnylam Pharmaceuticals stock opened at $320.00 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company’s fifty day moving average price is $386.86 and its two-hundred day moving average price is $425.68. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The company has a market capitalization of $42.28 billion, a price-to-earnings ratio of 1,333.33 and a beta of 0.35.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright lowered their target price on Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price for the company. Finally, Leerink Partners lowered their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $477.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.